Moderna NASDAQ: MRNA executives emphasized the company's evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development.
Read on marketbeat.com